ABBV:NYE-AbbVie Inc (USD)

COMMON STOCK | Drug Manufacturers—General | NYE

Last Closing Price

USD 73.37

Change

0.00 (0.00)%

Market Cap

USD 108.34B

Volume

8.06M

Average Target Price

USD 96.70 (+31.80%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

AbbVie Inc., a research-based biopharmaceutical company, develops and markets pharmaceutical products in the United States, Japan, Germany, Canada, France, Spain, Italy, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a biologic therapy administered as an injection for autoimmune and intestinal diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides SYNAGIS that protects at-risk infants from severe respiratory disease; KALETRA, a prescription anti-HIV-1 medicine; CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; and Lupron, a product for the palliative treatment of advanced prostate cancer, treatment of endometriosis and central precocious puberty, and for the treatment of patients with anemia caused by uterine fibroids. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; and Sevoflurane, an anesthesia product. It has collaborations with Calico Life Sciences LLC; Alector, Inc.; and Janssen Biotech, Inc. The company was incorporated in 2012 and is based in North Chicago, Illinois.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-04-05 )

Largest Industry Peers for Drug Manufacturers—General

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
JNJ Johnson & Johnson

N/A

USD353.72B 21.88 N/A
MRK Merck & Co., Inc

N/A

USD193.39B 18.12 N/A
NVS Novartis AG

N/A

USD189.40B 15.67 N/A
PFE Pfizer Inc

N/A

USD186.62B 10.78 N/A
LLY Eli Lilly and Company

N/A

USD133.66B 15.34 N/A
BMY Bristol-Myers Squibb Company

N/A

USD125.63B 27.27 N/A
AZN AstraZeneca PLC

N/A

USD115.90B 87.06 N/A
GSK GlaxoSmithKline plc

N/A

USD91.75B 36.73 N/A
AGN Allergan plc

N/A

USD57.81B 22.00 N/A

ETFs Containing ABBV

Symbol Name Weight Mer Price(Change) Market Cap
ACT AdvisorShares Vice ETF 5.92 % 0.99 %

N/A

USD0.01B
HHL:CA Harvest Healthcare Leader.. 5.72 % 1.15 %

N/A

USD0.33B
HHL-U:CA Harvest Healthcare Leader.. 5.72 % 1.15 %

N/A

N/A
FHI:CA CI First Asset Health Car.. 5.25 % 0.75 %

N/A

USD0.19B
LIFE:CA Evolve Global Healthcare .. 5.25 % 0.45 %

N/A

USD0.01B
FHI-B:CA CI First Asset Health Car.. 5.25 % 0.74 %

N/A

N/A
FDL First Trust Morningstar D.. 4.85 % 0.45 %

N/A

USD1.61B
DHS WisdomTree U.S. High Divi.. 4.80 % 0.38 %

N/A

USD0.84B
PJP Invesco Dynamic Pharmaceu.. 4.78 % 0.56 %

N/A

USD0.33B
WTEU:XETRA WisdomTree US Equity Inco.. 4.72 % 0.29 %

N/A

N/A
WTD9:XETRA WisdomTree US Equity Inco.. 4.72 % 0.29 %

N/A

N/A
WTDY:F WisdomTree US Equity Inco.. 4.72 % 0.35 %

N/A

N/A
WTD9:F WisdomTree US Equity Inco.. 4.72 % 0.29 %

N/A

N/A
DHSD:LSE WisdomTree US Equity Inco.. 4.72 % 0.29 %

N/A

N/A
DHSP:LSE WisdomTree US Equity Inco.. 4.72 % 0.29 %

N/A

N/A
DHSG:LSE WisdomTree US Equity Inco.. 4.72 % 0.35 %

N/A

N/A
DHS:LSE WisdomTree US Equity Inco.. 4.72 % 0.29 %

N/A

N/A
DHSA:LSE WisdomTree US Equity Inco.. 4.72 % 0.29 %

N/A

N/A
ZWH:CA BMO US High Dividend Cove.. 4.62 % 0.65 %

N/A

USD0.75B
ZWH-U:CA BMO US High Dividend Cove.. 4.62 % 0.65 %

N/A

N/A
RNDV First Trust US Equity Div.. 4.27 % 0.50 %

N/A

USD4.21M
DDIV First Trust Dorsey Wright.. 4.21 % 0.60 %

N/A

USD0.06B
HID:CA WisdomTree U.S. High Divi.. 4.06 % 0.40 %

N/A

USD4.31M
SDG iShares MSCI Global Impac.. 3.86 % 0.49 %

N/A

USD0.09B
SXLV:LSE SPDR S&P U.S. Health Care.. 3.68 % 0.15 %

N/A

USD0.18B
ZPDH:XETRA SPDR S&P U.S. Health Care.. 3.68 % 0.15 %

N/A

USD0.18B
ZPDH:F SPDR S&P U.S. Health .. 3.68 % 0.15 %

N/A

USD0.18B
IUHC:LSE iShares S&P 500 Health Ca.. 3.67 % 0.15 %

N/A

USD1.17B
IHCU:LSE iShares S&P 500 Health Ca.. 3.67 % 0.15 %

N/A

USD1.17B
QDVG:F iShares S&P 500 Health Ca.. 3.67 % 0.15 %

N/A

USD1.17B
QDVG:XETRA iShares S&P 500 Health Ca.. 3.67 % 0.15 %

N/A

USD1.17B
XUHC:XETRA Xtrackers MSCI USA Health.. 3.45 % 0.12 %

N/A

USD0.40B
XUHC:LSE Xtrackers MSCI USA Health.. 3.45 % 0.12 %

N/A

USD0.40B
XSHC:LSE Xtrackers MSCI USA Health.. 3.45 % 0.12 %

N/A

USD0.40B
VHT Vanguard Health Care Inde.. 3.11 % 0.10 %

N/A

USD10.48B
LNGR Global X Longevity Themat.. 3.03 % 0.50 %

N/A

USD0.02B
USMV:LSE Ossiam US Minimum Varianc.. 2.69 % 0.65 %

N/A

N/A
XHC:CA iShares Global Healthcare.. 2.51 % 0.63 %

N/A

USD0.29B
WHEA:LSE SPDR MSCI World Health Ca.. 2.39 % 0.30 %

N/A

USD0.30B
SPDV AAM S&P 500 High Dividend.. 2.35 % 0.29 %

N/A

USD0.04B
XDWH:F Xtrackers MSCI World Heal.. 2.33 % 0.30 %

N/A

USD0.47B
SDYL UBS ETRACS Monthly Pay 2x.. 2.33 % 0.30 %

N/A

USD0.01B
XDWH:LSE Xtrackers MSCI World Heal.. 2.33 % 0.30 %

N/A

USD0.47B
XDWH:XETRA Xtrackers MSCI World Heal.. 2.33 % 0.30 %

N/A

USD0.47B
SDY SPDR S&P Dividend ETF 2.28 % 0.35 %

N/A

USD17.42B
CUD:CA iShares US Dividend Growe.. 2.27 % 0.60 %

N/A

USD0.42B
USDV:LSE SPDR S&P US Dividend Aris.. 2.26 % 0.35 %

N/A

N/A
SPYD:XETRA SPDR S&P US Dividend Aris.. 2.26 % 0.35 %

N/A

USD2.77B
UDVD:LSE SPDR® S&P US Dividend Ar.. 2.26 % 0.35 %

N/A

USD2.77B
SPYD:F SPDR S&P US Dividend Aris.. 2.26 % 0.35 %

N/A

USD2.77B
ZDY-U:CA BMO US Dividend ETF (USD) 2.25 % 0.30 %

N/A

N/A
ZDY:CA BMO US Dividend ETF (CAD) 2.25 % 0.30 %

N/A

USD1.33B
CURE Direxion Daily Healthcare.. 1.96 % 1.08 %

N/A

USD0.12B
DEW WisdomTree Global High Di.. 1.96 % 0.58 %

N/A

USD0.08B
FDRR Fidelity Dividend ETF for.. 1.79 % 0.29 %

N/A

USD0.35B
DTN WisdomTree U.S. Dividend .. 1.73 % 0.38 %

N/A

USD0.54B
UC81:LSE UBS ETF - Bloomberg Barcl.. 1.68 % 0.18 %

N/A

N/A
SPYD SPDR Portfolio S&P 500 Hi.. 1.68 % 0.07 %

N/A

USD1.96B
UC82:LSE UBS ETF - Bloomberg Barcl.. 1.68 % 0.23 %

N/A

N/A
UEF7:F UBS ETF - Bloomberg Barcl.. 1.68 % 0.18 %

N/A

N/A
CAPS:CA Evolve Active US Core Equ.. 1.38 % 0.70 %

N/A

USD3.62M
ESGW Columbia Sustainable Glob.. 0.93 % 0.40 %

N/A

USD0.01B
UEF0:F UBS ETF - Bloomberg Barcl.. 0.88 % 0.23 %

N/A

N/A
UEF9:XETRA UBS ETF - Bloomberg Barcl.. 0.88 % 0.18 %

N/A

N/A
UC85:LSE UBS ETF - Bloomberg Barcl.. 0.88 % 0.23 %

N/A

N/A
UEF9:F UBS ETF - Bloomberg Barcl.. 0.88 % 0.18 %

N/A

N/A
UEF0:XETRA UBS ETF - Bloomberg Barcl.. 0.88 % 0.23 %

N/A

N/A
UC76:LSE UBS ETF - Bloomberg Barcl.. 0.88 % 0.18 %

N/A

N/A
LCRP:LSE SPDR Bloomberg Barclays 1.. 0.49 % 0.20 %

N/A

USD0.15B
LUSC:LSE SPDR Bloomberg Barclays 1.. 0.49 % 0.20 %

N/A

USD0.15B
SYBN:F SPDR Bloomberg Barclays 1.. 0.49 % 0.20 %

N/A

USD0.15B
SYBN:XETRA SPDR Bloomberg Barclays 1.. 0.49 % 0.20 %

N/A

USD0.15B
SYBF:XETRA SPDR Bloomberg Barclays 0.. 0.42 % 0.20 %

N/A

USD0.10B
SYBF:F SPDR Bloomberg Barclays 0.. 0.42 % 0.20 %

N/A

USD0.10B
SUSC:LSE SPDR Bloomberg Barclays 0.. 0.42 % 0.20 %

N/A

USD0.10B
SUSD:LSE SPDR Bloomberg Barclays 0.. 0.42 % 0.20 %

N/A

USD0.10B
SYBR:XETRA SPDR Bloomberg Barclays 1.. 0.41 % 0.20 %

N/A

USD0.06B
SYBR:F SPDR Bloomberg Barclays 1.. 0.41 % 0.20 %

N/A

USD0.06B
SYB1:F SPDR Bloomberg Barclays U.. 0.37 % 0.20 %

N/A

USD0.02B
SYB1:XETRA SPDR Bloomberg Barclays U.. 0.37 % 0.20 %

N/A

USD0.02B
NUBD Nuveen ESG U.S. Aggregate.. 0.00 % 0.20 %

N/A

USD0.10B
SPIB SPDR Portfolio Intermedia.. 0.00 % 0.07 %

N/A

USD5.33B
VDIV:XETRA Think Morningstar® High .. 0.00 % 0.00 %

N/A

N/A
BSCK Invesco BulletShares 2020.. 0.00 % 0.10 %

N/A

USD1.68B
RXD ProShares UltraShort Heal.. 0.00 % 0.95 %

N/A

USD2.76M
LQD iShares iBoxx $ Investmen.. 0.00 % 0.15 %

N/A

USD34.24B
GIGB Goldman Sachs Access Inve.. 0.00 % 0.14 %

N/A

USD0.59B
SPLB SPDR Portfolio Long Term .. 0.00 % 0.07 %

N/A

USD0.74B
BSCP Invesco BulletShares 2025.. 0.00 % 0.10 %

N/A

USD0.49B
KORP American Century Diversif.. 0.00 % 0.29 %

N/A

USD0.11B
AGGY WisdomTree Yield Enhanced.. 0.00 % 0.12 %

N/A

USD1.30B
GEND:LSE Lyxor Global Gender Equal.. 0.00 % 0.35 %

N/A

USD0.02B
RXD ProShares UltraShort Heal.. 0.00 % 0.95 %

N/A

USD2.76M
UC84:LSE UBS ETF - Bloomberg Barcl.. 0.00 % 0.00 %

N/A

N/A
IBDL iShares iBonds Dec 2020 T.. 0.00 % 0.10 %

N/A

USD1.24B
IBDN iShares iBonds Dec 2022 T.. 0.00 % 0.10 %

N/A

USD1.23B
IBDQ iShares iBonds Dec 2025 T.. 0.00 % 0.10 %

N/A

USD0.66B
IGIB iShares Intermediate-Term.. 0.00 % 0.06 %

N/A

USD9.41B
AWTM Aware Ultra-Short Duratio.. 0.00 % 0.23 %

N/A

USD0.43B
SPSB SPDR Portfolio Short Term.. 0.00 % 0.07 %

N/A

USD6.77B

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers—General)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -17.13% 20% F 73% C
Dividend Return N/A N/A N/A N/A N/A
Total Return -17.13% 20% F 72% C-
Trailing 12 Months  
Capital Gain -12.08% 20% F 72% C-
Dividend Return 3.85% 90% A- 75% C
Total Return -8.23% 20% F 75% C
Trailing 5 Years  
Capital Gain 27.36% 70% C- 87% B+
Dividend Return 24.72% 100% A+ 80% B-
Total Return 52.07% 80% B- 90% A-
Average Annual (5 Year Horizon)  
Capital Gain 10.11% 82% B- 76% C
Dividend Return 4.03% 82% B- 73% C
Total Return 14.15% 82% B- 80% B-
Risk Return Profile  
Volatility (Standard Deviation) 29.00% 9% F 21% F
Risk Adjusted Return 48.79% 45% F 53% F
Market Capitalization 108.34B 30% F 98% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers—General)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 13.91 90% A- 53% F
Price/Book Ratio N/A N/A N/A N/A N/A
Price / Cash Flow Ratio 8.13 90% A- 36% F
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital 30.34% 100% A+ 97% A+
Return on Assets 11.53% 100% A+ 96% A
Debt to Equity Ratio -770.37% 100% A+ 99% A+
Technical Ratios  
Short Ratio 6.62 10% F 10% F
Short Percent 5.53% 17% F 54% F
Beta 0.79 20% F 63% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Underpriced on cashflow basis

The stock is trading low compared to its peers on a price to cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

Superior Dividend Growth

This stock has shown top quartile dividend growth in the previous 5 years compared to its sector

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.